We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Concord Medical Opens Datong Meizhongjiahe Cancer Hospital

By HospiMedica International staff writers
Posted on 07 Jun 2016
Concord Medical Services (CMS, Beijing, China) has announced the preliminary opening of Datong Meizhongjiahe Cancer Hospital (Shanxi Province, China).

The 100-bed hospital is a Level-II specialty cancer hospital with radiation, imaging, test laboratory, radiotherapy, and diagnostic imaging equipment, including a linear accelerator and a magnetic resonance imaging (MRI) system. More...
The hospital is the first wholly owned hospital in the projected Meizhongjiahe-branded network of hospitals planned for Chinese Tier II and Tier III cities, and will complement CMS high-end hospitals in Tier I cities such as Beijing, Shanghai, and Guangzhou.

As of December 31, 2015, CMS operated a network of 127 centers with 76 hospital partners that spanned 53 cities and 25 provinces and administrative regions in China. Under long-term arrangements with top-tier hospitals in China, the company provides radiotherapy and diagnostic imaging equipment and manages the daily operations of these centers, which are located on the premises of its hospital partners. The Company also provides ongoing training to doctors and other medical professionals in its network of centers to ensure a high level of clinical care for patients.

“We are very pleased to celebrate the transformative milestone in the history of Concord Medical. This first wholly-owned domestic cancer hospital in China is an important step of our broad strategy to build a nationwide chain of free-standing cancer treatment and diagnosis centers under the brand ‘Meizhongjiahe’ in the future,” said Jianyu Yang, MD, chairman and CEO of CMS. “There is strong patient demand in Tier II and Tier III cities in China for advanced cancer diagnosis and treatments, and we see their challenge as ours.”

CMS is undergoing an expansion drive in the Chinese domestic market, and is currently establishing specialty cancer hospitals in Wuxi, Hangzhou, Taizhou, and Nanchang. In addition, as part of its high-end cancer hospital development strategy and oversea business extension, the company acquired Concord Cancer Hospital, a private hospital in Singapore in April 2015.

Related Links:
Concord Medical Services


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
MRI System
nanoScan MRI 3T/7T
IV Therapy Cart
Avalo I.V Therapy Cart
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.